Journal
MOLECULAR PHARMACEUTICS
Volume 10, Issue 2, Pages 586-597Publisher
AMER CHEMICAL SOC
DOI: 10.1021/mp300325v
Keywords
subunit vaccines; nanoparticles; elastin-like recombinamers (ELRs); Mycobacterium tuberculosis
Funding
- EU through the European Regional Development Fund (ERDF) from MICINN [MAT 2009-14195-C03-03, MAT-2010-15982, MAT2010-15310, ACI2009-0890, PRI-PIBAR-2011-1403]
- JCyL [VA034A09, VA049A11-2, VA152A12-2, VA155A12-2]
- CIBER-BBN
- JCyL
- Instituto de Salud Carlos III under the Network Center of Regenerative Medicine and Cellular Therapy of Castilla and Leon
Ask authors/readers for more resources
This study investigates both the physicochemical properties and immunogenicity of a genetically engineered elastin-like block corecombinamer (ELbcR) containing a major membrane protein sequence from Mycobacterium tuberculosis. The recombinant production of this ELbcR allows the production of large quantities of safe, antigenic particle-based constructs that directly and reversibly self-assemble into highly biocompatible, multivalent, monodisperse, and stable nanovesicles with a diameter of 55 nm from the same gene product using a highly efficient and cost-effective inverse transition cycling (ITC) procedure. The compositional complexity of these vesicles is retained after secondary processes such as endotoxin removal, sterilization, and lyophilization. An initial pro-chemotactic cytoldne response (IL-1 beta) followed by a pro-Th2/IL-5 response was observed in mice plasma following subcutaneous administration of the antigen-loaded nanovesicles in mice. This biphasic model of cytokine production was coupled with humoral isotype switching from IgM- to IgG-specific antibodies against the antigen, which was only observed in the presence of both the antigen and the polymer in the same construct and in the absence of additional adjuvants.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available